The Cigna Group vs Elevance Health, Inc.: Strategic Comparison

This in-depth comparison examines The Cigna Group and Elevance Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching The Cigna Group on its own, evaluating Elevance Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between The Cigna Group and Elevance Health, Inc. is widest.

On the headline numbers, The Cigna Group reports annual revenue of $274.9B against $199.1B for Elevance Health, Inc., while their respective market capitalizations stand at $71.9B and $80.0B. The Cigna Group is headquartered in United States and Elevance Health, Inc. operates from United States, and those different home markets shape how each company competes.

The Cigna Group: The Cigna Group is best understood as a pharmacy-services company attached to an employer health benefits business. Evernorth Health Services, built around the 2018 Express Scripts acquisition, generates most of the revenue, while Cigna Healthcare serves about 18.4 million medical customers in the U.S. and abroad (June 30, 2026). The company counted about 182.8 million total customer relationships at mid-2026 and is based in Bloomfield, Connecticut.

Elevance Health, Inc.: Elevance Health is one of the largest U.S. health insurers by revenue, with roughly 45 million medical members and about 104 million consumers served across its businesses. It sells Anthem Blue Cross and Blue Shield plans in 14 states, Wellpoint government plans in others, and pharmacy and health services through Carelon.

The Cigna Group and Elevance Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between The Cigna Group and Elevance Health, Inc..

The Cigna Group business model: Cigna makes money in two ways. Evernorth Health Services, the larger business by revenue, runs Express Scripts pharmacy benefit management, Accredo specialty pharmacy, home-delivery pharmacy, eviCore utilization management and MDLive virtual care; it earns dispensing margins, administrative and service fees, and purchasing economics on prescription drugs for health plans and employers. Cigna Healthcare sells employer and individual health coverage in the U.S. and internationally. Most of its U.S. medical customers are in self-funded (ASO) plans, where the employer pays claims and Cigna collects fees for networks, claims processing and care management, while insured plans earn premiums. In October 2025 Cigna announced a rebate-free Express Scripts model that shifts pharmacy economics toward upfront discounts and transparent fees.

Elevance Health, Inc. business model: Elevance makes money in two ways. First, its Health Benefits segment collects premiums from employers, individuals and government programs and pays members' medical claims; profit depends on keeping the benefit expense ratio (89.7% in Q2 2026) below premium levels and on fees for administering self-funded employer plans. Second, Carelon earns pharmacy and services revenue: CarelonRx manages prescription benefits and dispenses specialty drugs, while Carelon Services sells behavioral health, home-based care and risk-based care management, increasingly to outside health plans as well as Elevance's own members. Carelon produced $19.2B of operating revenue and $0.9B of operating gain in Q2 2026.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of The Cigna Group stack up against those of Elevance Health, Inc..

The Cigna Group competitive advantage: Cigna's edge is scale in pharmacy plus a capital-light medical business. Evernorth managed about 118 million pharmacy customers at June 30, 2026, giving it purchasing power with drug makers and pharmacies, and Accredo is one of the largest U.S. specialty pharmacies. Cigna Healthcare's focus on self-funded employers generates fee income with less underwriting risk than fully insured or government-heavy insurers, and Evernorth sells services to outside health plans that do not buy Cigna insurance.

Elevance Health, Inc. competitive advantage: Elevance's main edge is its Blue Cross Blue Shield licenses in 14 states, which give it dense local provider networks and strong brand recognition with employers, plus access to the national BlueCard network. Owning CarelonRx and Carelon Services lets it keep pharmacy and care-management revenue that rivals without those assets pay to third parties.

Future prospects matter as much as current results. The growth strategies below explain how The Cigna Group and Elevance Health, Inc. each plan to expand from here.

The Cigna Group growth strategy: Cigna's growth plan centers on Evernorth: winning PBM clients with the rebate-free and transparent pricing models, growing Accredo specialty pharmacy and biosimilar programs, and selling services such as EncircleRx for GLP-1 cost management and Embarc Benefit Protection for gene therapies to other health plans and employers. On the medical side, Cigna Healthcare targets employer growth in select markets, stop-loss and international health benefits. Capital deployment combines dividends and share buybacks with targeted deals rather than large insurance mergers.

Elevance Health, Inc. growth strategy: Elevance is pruning lower-margin business, such as exiting standalone Medicare Part D plans for 2026 and the D.C. Medicaid market, while investing in medical cost management, provider connectivity and Carelon. Recent deals that extend Carelon include BioPlus specialty pharmacy (2023), Kroger Specialty Pharmacy (2024) and CareBridge home-based care (reported at about $2.7B, 2024 to 2025).

A closer look at the financial trajectory of The Cigna Group and Elevance Health, Inc. rounds out the comparison.

The Cigna Group: Revenue grew from $160.4 billion in 2020 to $274.9 billion in 2025, largely from Evernorth pharmacy volume, specialty drugs and new PBM clients. 2025 shareholders' net income was $6.0 billion ($22.18 per share), up from $3.4 billion in 2024, when results included a $2.7 billion after-tax loss on the VillageMD investment. Adjusted income from operations was $8.0 billion ($29.84 per share) in 2025. In the first half of 2026 Cigna reported $140.2 billion in revenue and $3.3 billion in shareholders' net income, and it raised 2026 adjusted EPS guidance to at least $30.45. The quarterly dividend was raised to $1.56 per share in February 2026.

Elevance Health, Inc.: Revenue rose from $171.3B in 2023 to $177.0B in 2024 and $199.1B in 2025, helped by premium-rate increases, acquisitions and Medicare Advantage growth that offset Medicaid attrition. Net income was $5.662B in 2025 on operating income of $7.199B. Growth slowed in 2026 as the company deliberately shrank unprofitable Medicaid, Medicare Advantage and employer risk business: operating revenue was $49.5B in Q1 2026 and $49.8B in Q2 2026. In July 2026 Elevance raised full-year guidance to at least $20.10 GAAP diluted EPS and at least $27.00 adjusted EPS, with operating cash flow of at least $6.0B, and paid a $1.72 quarterly dividend.